Buy Generic Viagra,cialis,levitra Online Pharmacy – Buy Viagra, Cialis, Levitra,Kamagra,Caverta,Tadalis Online Without Prescription

January 8, 2010 — A large, new, multicenter survey has found that childhood abuse is highly prevalent among migraine patients and that migraine patients with a history of early-life abuse have significantly more comorbid pain conditions, including irritable bowel syndrome (IBS) and fibromyalgia (FM), compared with those without such a history.

The research appeared in Headache: The Journal of Head and Face Pain, published on behalf of the American Headache Society.

The study, the largest to date to look at early abuse in a migraine population, was conducted by the Women’s Issues Section Research Consortium of the American Headache Society. It included 1348 patients (88% women; mean age, 41 years) with migraine at 11 outpatient headache centers in the United States and Canada.

Using electronic questionnaires, researchers collected sociodemographic information, including age, sex, race, household income, educational level, and substance abuse. They assessed childhood abuse using the Childhood Trauma Questionnaire, a 28-item, self-reported measure of 5 categories of abuse: physical, sexual, and emotional abuse and physical and emotional neglect. Depression was assessed using the Patient Health Questionnaire and anxiety using the Beck Anxiety Inventory.

Headache disorder was determined using the International Classification of Headache Disorders, 2nd Edition, criteria.

Maltreatment Prevalence

The research appeared in 3 separate articles. In the first article, researchers discussed the prevalence of childhood maltreatment. They found that 58% of participants endured childhood abuse or neglect. Emotional abuse was reported most commonly (38%) and in higher severity (12% with “severe to extreme” abuse) than other abuses, such as physical and sexual abuse.

Emotional abuse is “very, very common” in this headache population, said the lead study author, Gretchen E. Tietjen, MD, professor and chair, Department of Neurology, University of Toledo, Ohio. “The rate was higher than previously reported, and it was surprising.”

In population studies, only about 10% of respondents report emotional abuse, she said.

Emotional abuse is relatively difficult to define and has only recently been recognized as a distinct entity, said Dr. Tietjen. This abuse, which can occur on a daily basis and often reflects a poor family environment, may have more dire and long-lasting consequences than other types of abuse.

Neglect, too, has received scant attention in studies even though it is the category of child maltreatment most frequently recorded by child protection agencies.

This part of the study also showed that more than 33% of respondents reported abuse in adulthood, predominantly (70%) between the ages of 18 and 30 years. Physical abuse in adulthood was reported by 20% and sexual abuse by 22%. “From an alternative perspective, of those reporting childhood maltreatment, 43% were revictimized in adulthood,” the study authors write.

Migraine Characteristics

The second article reviewed migraine characteristics and the differences among episodic headache (fewer than 15 headaches a month), frequent headache, and episodic headache that developed into chronic headache. About 40% of participants had migraine with aura, 34% had chronic migraine, and 26% a transformation from episodic to chronic headache.

After adjusting for all variables, including current depression and anxiety, only emotional abuse was associated with chronic migraine (odds ratio, 1.77) and transformational headaches (odds ratio, 1.89). “Having chronic headaches, or a headache all day every day, and transforming from episodic to chronic were tied not as much to the other abuses but to emotional abuse,” said Dr. Tietjen.

Patients who had experienced childhood emotional abuse also tended to develop migraines earlier, at a median of 16 vs 19 years of age for those without such abuse, she said.

Pain Conditions

The third analysis investigated the relationship between childhood abuse and comorbid pain conditions, including IBS, FM, chronic fatigue syndrome (CFS), interstitial cystitis, arthritis, endometriosis, uterine fibroids, and pelvic pain and cramps.

Comorbid pain conditions were common among participants — 25% had arthritis, 31% had IBS, 16% had CFS, and 10% had FM. Some 61% had at least 1 comorbid pain condition, 18% had 2, and 13% had 3 or more pain conditions. Those reporting emotional abuse or physical neglect had significantly more comorbid pain conditions compared with those without these childhood traumas.

“What was interesting and what makes one infer that there may be a causal relationship is the fact that the more severely abused you were and the more different types of abuse you had, the more different pain conditions you had,” said Dr. Tietjen.

The associations of maltreatment and pain were independent of depression and anxiety, both of which were highly prevalent in this population (28% had current depression and 56% had current anxiety). “This suggests that although depression is strongly associated with, and may be a sequela of, childhood maltreatment, emotional abuse and physical neglect each independently contributes to enhanced pain experience,” write the study authors.

From Stress to Headache

What is not clear is how childhood abuse may eventually lead to migraines and other pain conditions. Maltreatment at an early age could cause changes in areas of the brain, including the hippocampus and amygdala, and alter stress responses, said Dr. Tietjen. An alteration in cortisol in childhood “changes forever your stress response,” she noted. These changes may not be evident in childhood but develop over time, she said.

It is impossible to determine how an individual will react to the stress of abuse. It could depend on the severity of abuse, who the abuser was (whether it was a trusted family member or merely an acquaintance), and the age at which the abuse began, said Dr. Tietjen.

It also could depend on genetic makeup. Stress may actually change DNA to make a person more susceptible to the traumatic fallout of abuse. On the other hand, genes may make some people more resilient to the effects of stress.

“It’s probably a very complicated makeup of a lot of different genes and a lot of different things in the environment” that predisposes some people to develop pain and headache after exposure to stress, said Dr. Tietjen.

What might tie abuse and various pain syndromes together is what Dr. Tietjen called “central sensitization,” where stress pushes the central nervous system into overdrive. One of the characteristics of this state of central sensitivity is allodynia. Past research has shown that patients with migraine-related allodynia are more likely to have IBS, CFS, and other pain-related syndromes, said Dr. Tietjen.

Preventing Painful Conditions

However, there may be a way to prevent pain-related manifestations of childhood exposure to abuse. Dr. Tietjen believes that cognitive behavioral therapy, which teaches patients to better handle stress, could prevent painful conditions. She used the example of a 20-year-old woman with a history of abuse who comes in with a migraine. Treating that patient with cognitive behavioral therapy may prevent progression to chronic migraine or prevent FM, IBS, or other conditions that typically develop at a slightly later age.

“Cognitive behavioral therapy might be a good therapy under that circumstance because it changes the body’s response to stress. If you have an abnormal response to stress because of your past experiences, maybe this can help normalize your response.”

According to background information included in the articles, childhood maltreatment is a major public health problem. In the United States, there are nearly 1 million substantiated reports of physical and sexual abuse of children each year. Most reported cases involve neglect, followed by physical abuse then sexual abuse.

Objective: The aim of this study was to determine the effect of sildenafil on the uterine circulation and clitoral artery blood flow in postmenopausal women using color Doppler sonography.

Methods: The study population consisted of 25 volunteer naturally postmenopausal women (mean age, 50.2 ± 3.6 years). Color Doppler sonography was performed to measure the resistance and pulsatility indexes of the uterine arteries and peak systolic velocity, resistance, and pulsatility indexes of the clitoral arteries. One hour after administration of a single oral dose of 50 mg sildenafil citrate, the Doppler sonographic examination was repeated.

Results: After sildenafil administration, the mean resistance and pulsatility indexes of uterine artery were significantly lower (0.73 ± 0.08 vs 0.80 ± 0.07, P < .001 and 1.66 ± 0.50 vs 2.08 ± 0.52, P < .001, respectively) in comparison to baseline values, and the mean peak systolic velocity of clitoral artery was significantly higher (17.9 ± 8.6 cm/sec vs 12.9 ± 5.8 cm/sec, P < .001). Sildenafil did not cause any significant change in the mean resistance and pulsatility indexes of the clitoral artery (P = .683 and P = .714, respectively).

Conclusion: Sildenafil improves the clitoral and uterine blood flow in healthy postmenopausal women without any erotic stimulus. Further studies are needed to determine whether there are roles for sildenafil therapy in postmenopausal women and evaluation of clitoral blood flow by Doppler sonography.
Introduction

Female sexual dysfunction (FSD) is a multicausal and prevalent problem that can significantly affect the quality of life and interpersonal relationships of postmenopausal women.[1,2] Aging and the decline of ovarian hormonal secretion during the menopausal transition may alter libido and sexual response and functioning.[3-5] This decline relates more to decreasing estradiol concentrations than to androgen levels.[6] In addition to hormonal changes, chronic diseases and medications may also negatively affect vascular response of the end genital organs. Potential therapeutic options for some categories of FSD include hormonal and pharmacologic agents.[7-9] Since nitric oxide (NO) synthase isoforms have been identified in the uterine[10] and clitoral tissues,[11] the NO–cyclic guanosine monophosphate (cGMP) pathway, which is involved in penile erection and enhanced by sildenafil,[12,13] may also play a role in some components of female sexual arousal response. Sildenafil has been demonstrated to be safe and effective in treatment of male erectile dysfunction.[13,14] However, there are little data about the influence of sildenafil on vascular hemodynamics of genital tissues in women. A single randomized placebo-controlled trial of sildenafil treatment for female sexual arousal disorder (FSAD) in postmenopausal women suggests that the agent may be effective for a select population of women (ie, without concomitant lack of sexual desire or contributory emotional, relationship, or historical abuse issues).[15] Pfizer, the company that developed the drug, however, decided against seeking regulatory approval for its use in the treatment of FSAD because several large-scale placebo-controlled studies yielded inconclusive results.[16]

Measuring penile blood flow by color Doppler sonography has become a first-line test for evaluation of erectile dysfunction,[17] which is considered the male analogue to some components of FSAD. Clitoral blood flow measurements by color Doppler sonography may also be a reliable method to assess female sexual response.[18] The purpose of this study was to determine the effect of sildenafil on the uterine circulation and clitoral artery blood flow in postmenopausal women, by color Doppler ultrasound.

Sildenafil was the first oral compound to be approved for the treatment of erectile dysfunction. In this paper, we review the current knowledge of the effects of sildenafil on myocardial infarction and sudden cardiac death. The first factor we examine is the sexual activity itself. As several studies have shown, the relative risk for an acute coronary syndrome during intercourse is not very high. Several studies examining the effects of sildenafil on mortality have been published during recent years. The great majority of these studies found that sildenafil is not an extra risk factor for an acute coronary syndrome or sudden cardiac death. In 1997, the rate of myocardial infarction in men 55-64 years of age was 1542 per 1 000 000 in the US. According to this, the expected number of deaths as a result of myocardial infarction in patients 55-64 years of age receiving sildenafil, in the 24-hour period after use, from late March 1997 to mid November 1998, should have been 52. Instead, the number of reported deaths were only 15. One very optimistic finding was that sildenafil not only does not increase mortality, but in fact ‘preconditions’ the heart and has a cardioprotective effect. Besides, many studies have shown that sildenafil does not reduce the exercise tolerance in men with known coronary artery disease. As far as BP is concerned, the differences before and after the use of sildenafil are not clinically significant. The only contraindications for sildenafil are co-administration with a-adrenoceptor antagonists or with nitric oxide donors. According to the most recent studies, isoform 5 of phosphodiesterase has also been detected in the myocardium and controls the soluble pool of 3′, 5′-cyclic guanosine monophosphate (cGMP). Sildenafil is very specific for cGMP but it may increase cyclic adenosine monophosphate in the myocardium indirectly. This does not occur with small therapeutic doses of the drug. There is some dispute regarding the association of sildenafil with arrhythmias, where the available evidence is not clear. However, there are suspicions that sildenafil may cause sympathetic activation. The overall conclusion is that sildenafil is a safe drug and that its appropriate use does not seem to increase the risk for myocardial infarction or sudden cardiac death.
Introduction

Sildenafil was the first oral compound to be approved for the treatment of erectile dysfunction. It is a selective inhibitor of isoform 5 of phosphodiesterase (PDE5), which is the enzyme responsible for the breakdown of 3′, 5′-cyclic guanosine monophosphate (cGMP). The increase of cGMP leads to relaxation of the vascular smooth cells of the corpora cavernosa,[1,2] as well as the systemic and pulmonary vasculature.[2,3]

Sildenafil has been available for use in erectile dysfunction since March 1998. This drug has been associated with adverse cardiovascular events based on case reports.[4,5] This has led to hesitation to use sildenafil in patients with a history of heart disease,[4,5] for fear of adverse cardiac events during or after the sexual activity. Such concerns have never been proved in either randomized trials or retrospective analyses. In this paper we review the incidence of myocardial infarction and sudden death associated with sildenafil in the treatment of patients with erectile dysfunction.

In order to find the appropriate references for our review, we searched PubMed from January 1994 to September 2007. The following keywords were used: ’sildenafil’, ‘myocardial infarction’, ‘PDE-5′, ’sudden death’, ‘arrhythmia’, ‘erectile dysfunction’, ‘blood pressure’, ‘vardenafil’, and ‘tadalafil’. We chose randomized controlled studies, retrospective analyses, and case reports that were published in peer-reviewed journals and were most relevant to our subject. The number of studies was approximately 50. Also, the the reference lists of some selected articles were used to retrieve data.